Very recently, it was clearly demonstrated that CML CD34+ cells are characterized by the down-modulation of p53 targets and that drugs able to enhance p53 levels, together with c-MYC targeting drugs, promote CML cells selective apoptosis induction [103]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.